To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine ...

1-2 NORTH CHICAGO, Ill., Nov. 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest ...

For AbbVie, (NYSE: ABBV) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years. Here's how this drugmaker proved the bears ...

AbbVie Inc (NYSE:ABBV) was reduced by 15,000 shares, a 9.29% decrease, impacting the portfolio by -0.86%. The stock traded at an average price of $186.63 during the quarter and has seen a -11.39% ...

Overview: MedinCell S.A. is a pharmaceutical company based in France that develops long-acting injectables across various therapeutic areas, with a market cap of approximately €507.87 million.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.